dc.contributor.author | Selfe, J | |
dc.contributor.author | Shipley, JM | |
dc.date.accessioned | 2020-06-03T11:51:28Z | |
dc.date.issued | 2019-07-01 | |
dc.identifier.citation | Andrology, 2019, 7 (4), pp. 536 - 544 | |
dc.identifier.issn | 2047-2919 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3690 | |
dc.identifier.eissn | 2047-2927 | |
dc.identifier.doi | 10.1111/andr.12658 | |
dc.description.abstract | The insulin-like growth factor (IGF) axis plays key roles in normal tissue growth and development as well as in the progression of several tumour types and their subsequent growth and progression to a metastatic phenotype. This review explores the role of IGF system in normal germ cell development and function in addition to examining the evidence for deregulation of IGF signalling in cancer, with particular relevance to evidence supporting a role in testicular germ cell tumours (TGCTs). Despite the clear preclinical rationale for targeting the IGF axis in cancer, there has been a lack of progress in identifying which patients may benefit from such therapy. Future employment of agents targeting the IGF pathway is expected to concentrate on their use in combination with other treatments to prevent resistance and exploit their potential as chemo- and radiosensitizers. | |
dc.format | Print-Electronic | |
dc.format.extent | 536 - 544 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | WILEY | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Germ Cells | |
dc.subject | Animals | |
dc.subject | Humans | |
dc.subject | Neoplasms, Germ Cell and Embryonal | |
dc.subject | Testicular Neoplasms | |
dc.subject | Receptor, IGF Type 1 | |
dc.subject | Somatomedins | |
dc.subject | Drug Resistance, Neoplasm | |
dc.subject | Molecular Targeted Therapy | |
dc.subject | Carcinogenesis | |
dc.title | IGF signalling in germ cells and testicular germ cell tumours: roles and therapeutic approaches. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2019-05-05 | |
rioxxterms.versionofrecord | 10.1111/andr.12658 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2019-07 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Andrology | |
pubs.issue | 4 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Sarcoma Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Molecular Pathology | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Sarcoma Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Molecular Pathology | |
pubs.publication-status | Published | |
pubs.volume | 7 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Sarcoma Molecular Pathology | |
dc.contributor.icrauthor | Selfe, Joanna | |
dc.contributor.icrauthor | Shipley, Janet | |